XML 16 R4.htm IDEA: XBRL DOCUMENT v3.21.1
Combined Consolidated Statements of Operations - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Income Statement [Abstract]    
Revenue $ 605 $ 2,202
Operating expenses:    
Research and development (including amounts with related parties) 139,507 111,997
Selling, general and administrative (including amounts with related parties) 71,318 46,456
Impairment of intangible assets 10,660 0
Total operating expenses 221,485 158,453
Loss from operations (220,880) (156,251)
Other income (expense):    
Interest and investment income, net 2,435 2,442
Interest expense (including amounts with related parties) (9,074) (5,920)
Other income (expense), net (including amounts with related parties) 1,486 (534)
Total other expense (5,153) (4,012)
Loss before income taxes and noncontrolling interest (226,033) (160,263)
Income tax benefit 1,846 105
Net loss (224,187) (160,158)
Net loss attributable to noncontrolling interests, net of tax (2,336) (2,381)
Net loss attributable to ImmunityBio common stockholders $ (221,851) $ (157,777)
Net loss per ImmunityBio common share - basic and diluted $ (0.59) $ (0.43)
Weighted-average number of common shares used in computing net loss per share - basic and diluted 377,067,527 366,324,859